文献速递心脏核医学

18F-Flurpiridaz PET心肌血流量定量方法与软件包之间的比较、一致性和显著性界值

Comparison, Agreement, and Significance Cutoffs of 18F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages.
PubMed 文献 · J Nucl Med · 2025-11-03

本研究比较了三种18F-Flurpiridaz PET心肌血流量定量方法(ECTb、4DM、QPET软件)在405例药物负荷患者中的差异与一致性,并以有创冠状动脉造影为参考标准评估诊断性能。各软件包间一致性高(Fleiss κ 0.72–0.79),应力MBF和MFR的AUC在各方法间相似,支持这些平台在临床实践中的互操作性。

要点

  • 三种软件包定量18F-Flurpiridaz MBF的一致性高,Fleiss κ为0.72–0.79。
  • 应力MBF和MFR的诊断AUC在各方法间相似,患者水平为0.71–0.74。
  • 各软件包间的高一致性和相似定量为临床互操作性奠定基础。

核心结论

  • 所有软件包均显示出高的18F-Flurpiridaz MBF定量一致性,为这些平台在临床实践中的互操作性铺平了道路。

研究设计与样本

  • 比较三种18F-Flurpiridaz MBF定量方法(ECTb、4DM、QPET软件),纳入3期18F-Flurpiridaz PET试验(NCT03354273)中所有可评估的药物负荷患者(n=405)。
  • 采用Bland-Altman图确定MBF定量方法间的绝对差异,Fleiss κ评估软件包间一致性,Cohen κ评估两两比较的一致性。
  • 以定量有创冠状动脉造影为参考标准,通过受试者工作特征分析曲线下面积(AUC)确定应力MBF和心肌血流储备(MFR)的诊断性能。

主要发现

  • ECTb与4DM之间平均应力MBF差异范围为0.23至0.29 mL/min/g,MFR差异范围为0.37至0.40 mL/min/g。
  • ECTb与QPET之间平均应力MBF差异范围为0.09至0.11 mL/min/g,MFR差异范围为0.36至0.38 mL/min/g。
  • QPET与4DM之间平均应力MBF差异范围为0.25至0.26 mL/min/g,MFR差异范围为0.39至0.40 mL/min/g。
  • 软件包间一致性高,应力MBF的Fleiss κ范围为0.77至0.79,MFR的Fleiss κ范围为0.72至0.75,两两比较结果相似。
  • 对于狭窄至少70%的冠状动脉区域,患者水平中位应力MBF和MFR的AUC分别为0.73–0.74和0.71–0.73,每血管水平汇总冠状动脉分布分别为0.75–0.77和0.74–0.75。

临床怎么用

  • 原文结论指出,所有软件包的高一致性和相似定量为这些平台在临床实践中的互操作性铺平了道路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-flurpiridaz is a novel PET myocardial perfusion radiotracer with a high myocardial extraction fraction and low positron range, providing high-resolution images. Additionally, the linear relationship between 18F-flurpiridaz myocardial extraction and myocardial blood flow (MBF) over a wide range of flow values permits accurate MBF measurement. Several groups have developed strategies to quantitate 18F-flurpiridaz MBF with methodologic differences. These methods have not previously undergone head-to-head comparisons. Methods: Three methods of 18F-flurpiridaz MBF quantitation were compared using Emory Cardiac Toolbox (ECTb; Syntermed), 4DM (INVIA), and Quantitative PET (QPET; Cedars-Sinai) software. All evaluable pharmacologic stress patients from the phase 3 18F-flurpiridaz PET trial (NCT03354273) of 18F-flurpiridaz were included (n = 405). We adopted Bland-Altman plots to determine absolute differences between MBF quantitative methods, Fleiss κ for agreement across software packages, and Cohen κ for agreement of pairwise comparisons. Diagnostic performances of stress MBF and myocardial flow reserve (MFR) were determined by performing receiver-operating-characteristic analysis for areas under the curve (AUCs), using quantitative invasive coronary angiography as the reference standard. Results: Differences in mean stress MBF and MFR between methods across coronary territory distributions ranged from 0.23 to 0.29 mL/min/g and from 0.37 to 0.40 mL/min/g for ECTb and 4DM, respectively; from 0.09 to 0.11 mL/min/g and from 0.36 to 0.38 mL/min/g for ECTb and QPET, respectively; and from 0.25 to 0.26 mL/min/g and from 0.39 to 0.40 mL/min/g for QPET and 4DM, respectively. There was substantial agreement across software packages, with the Fleiss κ ranging from 0.77 to 0.79 and 0.72 to 0.75 for stress MBF and MFR, respectively. Similar results were found in pairwise comparisons. For coronary artery territories with at least 70% stenosis, median stress MBF and MFR AUCs were 0.73-0.74 and 0.71-0.73, respectively, when evaluated on a per-patient basis, and 0.75-0.77 and 0.74-0.75, respectively, in pooled coronary distributions on a per-vessel basis across all methods. Conclusion: All software packages demonstrated high agreement and similar 18F-flurpiridaz MBF quantitation, paving the way for the interoperability of these platforms in clinical practice.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Packard RRS, Buckley C, Cooke CD, et al. Comparison, Agreement, and Significance Cutoffs of 18F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages. J Nucl Med. 2025. PMID: 40774699. doi:10.2967/jnumed.124.269398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。